These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36601751)

  • 21. Enzyme replacement therapy in mucopolysaccharidosis type I: progress and emerging difficulties.
    Wraith JE
    J Inherit Metab Dis; 2001 Apr; 24(2):245-50. PubMed ID: 11405343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant encapsulated cells overexpressing alpha-L-iduronidase correct enzyme deficiency in human mucopolysaccharidosis type I cells.
    Baldo G; Quoos Mayer F; Burin M; Carrillo-Farga J; Matte U; Giugliani R
    Cells Tissues Organs; 2012; 195(4):323-9. PubMed ID: 21778683
    [TBL] [Abstract][Full Text] [Related]  

  • 23. OCT imaging of macular cysts and treatment response with nepafenac in mucopolysaccharidosis type 1.
    Yılmaz Çebi A; Hepokur M
    Ophthalmic Genet; 2023 Jun; 44(3):273-275. PubMed ID: 35876331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Specific antibody titer alters the effectiveness of intrathecal enzyme replacement therapy in canine mucopolysaccharidosis I.
    Dickson PI; Ellinwood NM; Brown JR; Witt RG; Le SQ; Passage MB; Vera MU; Crawford BE
    Mol Genet Metab; 2012 May; 106(1):68-72. PubMed ID: 22402327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liver-directed gene therapy corrects cardiovascular lesions in feline mucopolysaccharidosis type I.
    Hinderer C; Bell P; Gurda BL; Wang Q; Louboutin JP; Zhu Y; Bagel J; O'Donnell P; Sikora T; Ruane T; Wang P; Haskins ME; Wilson JM
    Proc Natl Acad Sci U S A; 2014 Oct; 111(41):14894-9. PubMed ID: 25267637
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mucopolysaccharidoses and the eye.
    Ashworth JL; Biswas S; Wraith E; Lloyd IC
    Surv Ophthalmol; 2006; 51(1):1-17. PubMed ID: 16414358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid.
    Dickson P; McEntee M; Vogler C; Le S; Levy B; Peinovich M; Hanson S; Passage M; Kakkis E
    Mol Genet Metab; 2007 May; 91(1):61-8. PubMed ID: 17321776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alpha-L-iduronidase and enzyme replacement therapy for mucopolysaccharidosis I.
    Brooks DA
    Expert Opin Biol Ther; 2002 Dec; 2(8):967-76. PubMed ID: 12517274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune response hinders therapy for lysosomal storage diseases.
    Ponder KP
    J Clin Invest; 2008 Aug; 118(8):2686-9. PubMed ID: 18654672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose enzyme replacement therapy in murine Hurler syndrome.
    Ou L; Herzog T; Koniar BL; Gunther R; Whitley CB
    Mol Genet Metab; 2014 Feb; 111(2):116-22. PubMed ID: 24100243
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A deletion of IDUA exon 10 in a family of Golden Retriever dogs with an attenuated form of mucopolysaccharidosis type I.
    Faller KME; Ridyard AE; Gutierrez-Quintana R; Rupp A; Kun-Rodrigues C; Orme T; Tylee KL; Church HJ; Guerreiro R; Bras J
    J Vet Intern Med; 2020 Sep; 34(5):1813-1824. PubMed ID: 32785987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correction of clinical manifestations of canine mucopolysaccharidosis I with neonatal retroviral vector gene therapy.
    Traas AM; Wang P; Ma X; Tittiger M; Schaller L; O'donnell P; Sleeper MM; Vite C; Herati R; Aguirre GD; Haskins M; Ponder KP
    Mol Ther; 2007 Aug; 15(8):1423-31. PubMed ID: 17519893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse.
    Wang D; Belakhov V; Kandasamy J; Baasov T; Li SC; Li YT; Bedwell DM; Keeling KM
    Mol Genet Metab; 2012 Jan; 105(1):116-25. PubMed ID: 22056610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.
    Jameson E; Jones S; Remmington T
    Cochrane Database Syst Rev; 2016 Apr; 4():CD009354. PubMed ID: 27033167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved retroviral vector design results in sustained expression after adult gene therapy in mucopolysaccharidosis I mice.
    Herati RS; Ma X; Tittiger M; Ohlemiller KK; Kovacs A; Ponder KP
    J Gene Med; 2008 Sep; 10(9):972-82. PubMed ID: 18613275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glycosaminoglycan storage in neuroanatomical regions of mucopolysaccharidosis I dogs following intrathecal recombinant human iduronidase.
    Chen A; Vogler C; McEntee M; Hanson S; Ellinwood NM; Jens J; Snella E; Passage M; Le S; Guerra C; Dickson P
    APMIS; 2011 Aug; 119(8):513-21. PubMed ID: 21749451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Corneal endothelium in mucopolysaccharide storage disorders. Morphologic studies in animal models.
    Mollard RJ; Telegan P; Haskins M; Aguirre G
    Cornea; 1996 Jan; 15(1):25-34. PubMed ID: 8907377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of lithium administration on vertebral bone disease in mucopolysaccharidosis I dogs.
    Lau YK; Peck SH; Arginteanu T; Wu M; Lin M; Shore EM; Klein PS; Casal ML; Smith LJ
    Bone; 2022 Jan; 154():116237. PubMed ID: 34695616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of tendon and ligament microstructure and mechanical properties in a canine model of mucopolysaccharidosis I.
    Lau YK; Iyer K; Shetye S; Friday CS; Dodge GR; Hast MW; Casal ML; Gawri R; Smith LJ
    J Orthop Res; 2024 Jul; 42(7):1409-1419. PubMed ID: 38368531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tralesinidase Alfa Enzyme Replacement Therapy Prevents Disease Manifestations in a Canine Model of Mucopolysaccharidosis Type IIIB.
    Ellinwood NM; Valentine BN; Hess AS; Jens JK; Snella EM; Jamil M; Hostetter SJ; Jeffery ND; Smith JD; Millman ST; Parsons RL; Butt MT; Chandra S; Egeland MT; Assis AB; Nelvagal HR; Cooper JD; Nestrasil I; Mueller BA; Labounek R; Paulson A; Prill H; Liu XY; Zhou H; Lawrence R; Crawford BE; Grover A; Cherala G; Melton AC; Cherukuri A; Vuillemenot BR; Wait JCM; O'Neill CA; Pinkstaff J; Kovalchin J; Zanelli E; McCullagh E
    J Pharmacol Exp Ther; 2022 Sep; 382(3):277-286. PubMed ID: 35717448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.